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INTRODUCTION
• In non-pregnant “quitters,” adherence to nicotine 
replacement therapy (NRT) increases smoking 
cessation. 
• Only 7-30% of pregnant women who received 
NRT reported finishing a complete course
• A potential reason for the apparently lower 
efficacy of NRT in pregnancy may be poor 
adherence to treatment.
• We used data from a placebo randomised trial of 
1050 pregnant women to nicotine replacement 
therapy (NRT) or placebo to investigate 
relationships between adherence to placebo or 
NRT patches and cessation in pregnancy
OBJECTIVES
In this study, we investigated:
1. Which participant characteristics are associated 
with adherence to trial treatments
2. The relationship between trial participants’ 
adherence to treatment patches and the odds of 
smoking cessation
3. Whether reverse causation explains any 
apparent adherence-cessation association
4. Whether there is evidence of an interaction 
between adherence, type of patch used (i.e. 
placebo or nicotine) and the odds of cessation
METHODS
The methods for the objectives stated above are as 
follows:
1. Multivariable linear regression was used to 
determine which patient characteristics were 
associated with the number of patches used, 
using a stepwise backwards model building 
strategy.
2. Multivariable logistic regression was used to 
investigate the relationship between adherence 
and smoking cessation. Treatment adherence 
and heaviness of smoking were considered a-
priori confounders. 
3. Logistic regression between adherence and 
cessation at delivery was conducted in a group 
restricted to those assigned NRT patches and 
who achieved abstinence at one month post-quit 
date.
4. Logistic regression for cessation at delivery with 
an interaction between NRT assignment and 
adherence (high vs. low based) was carried out 
to investigate whether higher use of NRT 
patches are associated with increased cessation.
CONCLUSIONS
• Greater adherence was seen with NRT patches, and greater adherence with NRT patches 
increased the odds of smoking cessation. 
• If used sufficiently, NRT patches may be effective for at least some pregnant women who try 
to stop smoking. Trials testing interventions which encourage women’s adherence to higher 
dose NRT are indicated.
ACKNOWLEDGEMENTS
LRV’s studentship, provided by the UK Centre for Tobacco and Alcohol Studies (UKCTAS), was funded by the UK Clinical Research Collaboration (UKCRC). LRV, TC, SC and 
PA are members of the NIHR School for Primary Care Research. LRV, TC, SC, PA and JLB are members of the UK Centre for Tobacco and Alcohol Studies 
(http://www.ukctas.ac.uk). Funding from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Medical Research Council and 
the National Institute of Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The research was supported by the 
National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East Midlands at NHS Nottingham City CCG.
RESULTS
OBJECTIVE 1. – Factors associated with adherence (n=957)
OBJECTIVE 2. – The association between adherence and cessation (n=957)
• For each extra day trial patches were used, up to 1 month, the odds of cessation at 1 month 
increased by 11% (adjusted OR 1.11, 95%CI 1.08 to 1.13, p<0.001). 
• For each extra day trial patches were used, up to eight weeks, the odds of cessation at 
delivery increased by 6% (adjusted OR 1.06, 95%CI 1.03 to 1.09, p<0.001).
OBJECTIVE 3. – Investigation of whether failure to quit results in reduced adherence 
(n=167)
• No association between adherence and cessation was observed when the group of participants 
was restricted to a subgroup where reverse causation was not possible (OR: 0.63, 95%CI: 
0.31-1.27, p=0.196). 
OBJECTIVE 4. – Investigating the interaction between assignment to NRT and 
adherence (n=957) 
• There was no difference in cessation between high and low adherence to placebo patches 
amongst users (OR 0.94, 95%CI 0.47 to 1.88, p=0.858). 
BUT…
• In NRT users, highly adherent women were more likely to achieve cessation than less 
adherent women (OR 2.47, 95%CI 1.32 to 4.63, p=0.004).
Adherence reported at 1m (0-4WKS) Adherence reported at delivery (0-8WKS)
Characteristic Adjusted β, (95%CI) Characteristic Adjusted β, (95%CI)
Baseline cotinine -0.08 (-0.18,-0.01) HSI -0.27 (-0.50, -0.05)
Allocation to NRT 2.59 (1.50, 3.68) Allocation to NRT 0.51 (0.29, 3.68)
